Nuveen Asset Management, LLC Evelo Biosciences, Inc. Transaction History

Nuveen Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.46 - $3.55 $140,414 - $341,417	-96,174 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.66 - $6.63 $4,266 - $10,634	1,604 Added 1.7%	96,174 $310,000
Q4 2021 Feb 14, 2022	SELL	$6.07 - $12.0 $42,277 - $83,580	-6,965 Reduced 6.86%	94,570 $685,000
Q3 2021 Nov 12, 2021	SELL	$6.79 - $13.9 $46,654 - $95,506	-6,871 Reduced 6.34%	101,535 $847,000
Q2 2021 Aug 16, 2021	BUY	$9.43 - $16.6 $395,183 - $695,656	41,907 Added 63.02%	108,406 $1.49 Million
Q1 2021 May 17, 2021	BUY	$9.71 - $18.6 $105,324 - $201,754	10,847 Added 19.49%	66,499 $712,000
Q4 2020 Feb 16, 2021	BUY	$3.91 - $12.28 $21,774 - $68,387	5,569 Added 11.12%	55,652 $672,000
Q3 2020 Nov 16, 2020	BUY	$3.81 - $5.73 $66,774 - $100,423	17,526 Added 53.83%	50,083 $264,000
Q2 2020 Aug 14, 2020	SELL	$3.53 - $6.12 $14,861 - $25,765	-4,210 Reduced 11.45%	32,557 $160,000
Q1 2020 May 14, 2020	BUY	$3.21 - $7.06 $7,614 - $16,746	2,372 Added 6.9%	36,767 $137,000
Q3 2019 Nov 14, 2019	SELL	$5.45 - $8.8 $13,625 - $22,000	-2,500 Reduced 6.78%	34,395 $210,000
Q2 2019 Aug 15, 2019	BUY	$6.52 - $9.42 $240,555 - $347,550	36,895 New	36,895 $331,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.